pharma · No medical condition. · Generalized Myasthenia Gravis
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Phase 1 · other · Schizophrenia
TV-44749 is an investigational intramuscular formulation of olanzapine being developed by Lacuna Pharma Pty Ltd for schizophrenia. The program is currently in Phase 1 development, with an active open-label bioavailability trial (TV44749-BA-10196) comparing TV-44749 to oral olanzapine in participants with schizophrenia.
Internal code TV44749-BA-10196
TV-44749 is an investigational intramuscular formulation of olanzapine being developed by Lacuna Pharma Pty Ltd for schizophrenia. The program is currently in Phase 1 development, with an active open-label bioavailability trial (TV44749-BA-10196) comparing TV-44749 to oral olanzapine in participants with schizophrenia. Olanzapine is an established atypical antipsychotic approved globally for schizophrenia management; this trial appears designed to establish the comparative bioavailability profile of the investigational formulation against the oral reference standard.
Lacuna Pharma's strategy centers on characterizing TV-44749's pharmacokinetic properties relative to conventional oral olanzapine therapy. The Phase 1 bioavailability study represents an early-stage clinical assessment, with no regulatory approvals yet disclosed for TV-44749 itself. Olanzapine as a comparator is widely approved across major markets: the United States (multiple generic sponsors), European Union (nine marketing authorization holders), Australia (PBS-listed), Japan (approved December 2017), and China (clinical trials ongoing). The trial's open-label design and bioavailability focus suggest Lacuna Pharma is establishing foundational pharmacokinetic data to support future development decisions.
Key milestones remain undisclosed, including expected next trial phases, regulatory interactions, and commercial timelines. The competitive schizophrenia market includes established agents such as risperidone, aripiprazole, paliperidone, and asenapine, alongside newer entrants. TV-44749's development trajectory and clinical significance will depend on whether the bioavailability data supports differentiation or improved clinical outcomes versus existing therapies.
Schizophrenia affects millions globally and requires long-term antipsychotic management. While oral olanzapine is well-established, alternative formulations and delivery routes remain clinically relevant for improving adherence, reducing pill burden, and optimizing therapeutic outcomes. Long-acting intramuscular formulations of antipsychotics have demonstrated clinical value in schizophrenia management by reducing relapse rates and improving medication adherence in populations with poor compliance to daily oral therapy.
The schizophrenia therapeutics market is substantial and competitive. Established agents including risperidone (APO-RISPERIDONE), aripiprazole (ABILIFY), paliperidone (INVEGA), asenapine (SAPHRIS), brexpiprazole (REXULTI), and lumateperone (CAPLYTA/REAGILA) compete across oral, intramuscular, and long-acting formulations. Newer agents such as ulotaront (ADASUVE) and dexmedetomidine (DEXDOR) address acute agitation. The market continues to value innovations that improve tolerability, reduce extrapyramidal side effects, or enhance adherence.
TV-44749's commercial significance depends on whether the intramuscular formulation offers pharmacokinetic or clinical advantages over existing olanzapine formulations and competitors. If bioavailability data support a favorable profile—such as improved absorption, reduced variability, or enhanced tolerability—the program could address unmet needs in patients requiring injectable antipsychotics. However, the competitive landscape is mature, and differentiation will be critical for market penetration. Current development status and timeline remain limited, making forward commercial projections premature.
Drug Class: Atypical antipsychotic (second-generation antipsychotic).
Mechanism of Action: Not yet disclosed for TV-44749; olanzapine acts as a dopamine D2 and serotonin 5-HT2A receptor antagonist, with additional activity at multiple other receptors.
Molecular Type/Modality: Small molecule; TV-44749 is an investigational formulation.
Route of Administration: Intramuscular injection (TV-44749); comparator is oral olanzapine.
Target: Not yet disclosed for TV-44749.
Related Therapies: Olanzapine is available in multiple formulations globally (oral tablets, orally disintegrating tablets, intramuscular injection). Competitive agents in schizophrenia include risperidone, aripiprazole, paliperidone, asenapine, brexpiprazole, and lumateperone.
First Approval (Olanzapine): Olanzapine has been approved in the United States, European Union, Australia, Japan, and China across multiple sponsors and formulations since the 1990s.
Patent Status: Not yet disclosed for TV-44749.
Also known as: schizophrenia 12, schizophrenia (disease), SCZD
A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.
ClinicalTrials.gov lists 2,921 registered studies for Schizophrenia (AACT aggregate).
Phase breakdown: NA (1,441), PHASE4 (414), PHASE3 (377), PHASE2 (297), PHASE1 (276), PHASE1/PHASE2 (52), PHASE2/PHASE3 (42), EARLY_PHASE1 (22)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005090), Orphanet — schizophrenia, NCT00000371, NCT00000372, NCT00000374, NCT00000387, NCT00001192, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Open-Label Bioavailability Trial (TV44749-BA-10196)
Active Phase 1 open-label trial assessing comparative bioavailability of TV-44749 to oral olanzapine in participants with schizophrenia.
The schizophrenia market includes multiple established antipsychotics across oral and injectable formulations. Risperidone (APO-RISPERIDONE, Servier Laboratories) and aripiprazole (ABILIFY, Alphapharm Pty Ltd) are widely available generics. Paliperidone (INVEGA, Janssen-Cilag Pty Ltd) offers long-acting intramuscular options. Asenapine (SAPHRIS, Organon Pharma Pty Ltd) provides sublingual dosing. Brexpiprazole (REXULTI, Amneal Pharma Europe Ltd) and lumateperone (REAGILA) represent newer oral agents. Loxapine (ADASUVE) and dexmedetomidine (DEXDOR) address acute agitation. Vanda Pharmaceuticals markets iloperidone (FANAPTUM) and tasimelteon (HETLIOZ) for related indications.
Olanzapine itself is widely available as a generic across multiple manufacturers in the United States (36+ ANDA approvals), European Union (9 marketing authorization holders), Australia (PBS-listed), Japan, and China. TV-44749, if approved, would enter a mature market with established olanzapine formulations and numerous competing agents. Differentiation would require demonstrable advantages in bioavailability, tolerability, efficacy, or adherence outcomes versus existing therapies.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| FANAPTUM | Vanda Pharmaceuticals Netherlands B.V. | — | approved |
| INVEGA | Janssen-Cilag Pty Ltd | — | approved |
| ABILIFY | Alphapharm Pty Ltd | — | approved |
| APO-RISPERIDONE | Servier Laboratories (Aust.) Pty. | — | approved |
| HETLIOZ | Vanda Pharmaceuticals Netherlands B.V. | — | approved |
| SONATA | Teva Pharma GmbH | — | approved |
| REXULTI | Amneal Pharma Europe Ltd | — | approved |
| SAPHRIS | Organon Pharma Pty Ltd | — | approved |
| ADASUVE | — | — | approved |
| PFIZER AUSTRALIA PTY LTD | Pfizer Australia Pty Ltd | — | approved |
| REAGILA | — | — | approved |
| DEXDOR | — | — | approved |
| ZIPRASIDONE HYDROCHLORIDE | — | Dopamine D2 receptor antagonist | Approved |
| TRIFLUOPERAZINE HYDROCHLORIDE | — | D2-like dopamine receptor antagonist | Approved |
| THIOTHIXENE | — | Dopamine D2 receptor antagonist | Approved |
| SAMIDORPHAN L-MALATE | — | Delta opioid receptor partial agonist | Approved |
| RISPERIDONE | — | Serotonin 2a (5-HT2a) receptor antagonist | Approved |
| QUETIAPINE FUMARATE | — | Serotonin 2c (5-HT2c) receptor antagonist | Approved |
| PROCHLORPERAZINE | — | Dopamine D2 receptor antagonist | Approved |
| PERPHENAZINE | — | Dopamine D2 receptor antagonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Olanzapine (Comparator) Regulatory Status:
TV-44749 Regulatory Status: Not yet disclosed. No approvals, regulatory designations, or interactions documented.
TV-44749 is an investigational intramuscular formulation of olanzapine being developed by Lacuna Pharma Pty Ltd for schizophrenia. It is currently in Phase 1 development.
TV-44749 is being investigated for schizophrenia, a chronic psychiatric disorder requiring long-term antipsychotic management.
Lacuna Pharma Pty Ltd is the sponsor of TV-44749. No development partners have been disclosed.
TV-44749 is in Phase 1 development. An active open-label bioavailability trial (TV44749-BA-10196) is comparing TV-44749 to oral olanzapine in participants with schizophrenia.
TV-44749 is administered as an intramuscular injection, in contrast to the oral comparator olanzapine.
Olanzapine is an atypical antipsychotic that acts as a dopamine D2 and serotonin 5-HT2A receptor antagonist, with activity at multiple other receptors. This mechanism helps reduce psychotic symptoms in schizophrenia.
Yes, olanzapine is widely approved globally across the United States, European Union, Australia, Japan, and China. Multiple generic formulations are available.
The trial is an open-label Phase 1 study designed to assess the comparative bioavailability of TV-44749 to oral olanzapine in participants with schizophrenia, establishing foundational pharmacokinetic data.
Competitors include risperidone (APO-RISPERIDONE), aripiprazole (ABILIFY), paliperidone (INVEGA), asenapine (SAPHRIS), brexpiprazole (REXULTI), and lumateperone (REAGILA), among others.
No regulatory approvals for TV-44749 have been disclosed. The program is in Phase 1 development with no approvals in the United States, European Union, Australia, Japan, or China.
The mechanism of action for TV-44749 has not yet been disclosed. As an olanzapine formulation, it is expected to function as an atypical antipsychotic, but specific details are not available.
The expected timeline for TV-44749 availability is not yet disclosed. The program is in Phase 1, and typical development timelines for antipsychotics span several years.
Intramuscular formulations may improve medication adherence, reduce pill burden, and provide sustained therapeutic levels in patients with schizophrenia who have difficulty with daily oral medication compliance.
Specific enrollment numbers for the TV44749-BA-10196 trial have not been disclosed.
The specific primary endpoints of the bioavailability trial have not been disclosed. The trial is designed to assess comparative bioavailability of TV-44749 versus oral olanzapine.
No development or commercialization partners have been disclosed for TV-44749. Lacuna Pharma Pty Ltd is the sole sponsor.
While olanzapine is well-established, alternative formulations and delivery routes remain clinically relevant for improving adherence and reducing relapse in schizophrenia patients with poor compliance to daily oral therapy.
TV44749-BA-10196 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Lacuna Pharma's Phase 1 bioavailability trial represents an early-stage characterization of TV-44749's pharmacokinetic profile. The open-label design and focus on comparative bioavailability suggest the sponsor is establishing foundational data to support future development decisions, regulatory interactions, and potential differentiation versus existing olanzapine formulations.
Competitive Implications: Olanzapine is a mature, widely-available generic with established clinical efficacy and safety. TV-44749 enters a crowded market with multiple competing antipsychotics and existing olanzapine formulations. Success will require demonstrable clinical or pharmacokinetic advantages—such as improved absorption, reduced variability, enhanced tolerability, or improved adherence—to justify differentiation and market adoption.
Future Catalysts: Key milestones include Phase 1 bioavailability data readout, regulatory feedback on development strategy, advancement to Phase 2 efficacy/safety trials (if warranted), and potential regulatory submissions. Timeline and next development phase remain undisclosed.
Expected Milestones: Not yet disclosed. Typical progression would include Phase 1 completion, regulatory interactions with health authorities, Phase 2 efficacy and safety studies, and potential Phase 3 pivotal trials if clinical differentiation is demonstrated.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.